Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Yesterday the FDA proposed removing GLP-1s from the 503B bulk list, and I spoke to Kurt Lunkwitz from ProRx to talk about changes to GLP-1 compounding
If you are ready to find out whether B12 deficiency may be contributing to your symptoms, scheduling a consultation is a straightforward first step
Tell your provider about all your current medications before you start oral semaglutide for weight loss through our Seattle clinic.
And it should always be said that its important to consult your healthcare professional before taking any new supplement or medication
Weight loss may indirectly improve some metabolic markers, but it does not replace thyroid hormone therapy
